Columbia Asset Management Grows Position in Pfizer Inc. $PFE

Key Points

• Columbia Asset Management increased its stake in Pfizer by 9.4%, bringing its total shares to 186,168, valued at approximately $4.5 million.
• Several major institutional investors, including Vanguard Group and Amundi, have also raised their holdings in Pfizer, contributing to a total of 68.36% institutional ownership.
• Pfizer reported a quarterly revenue of $14.65 billion, exceeding analysts' expectations and marking a 10.3% increase year-over-year; the company's FY 2025 EPS guidance is set at 2.900-3.100.

Columbia Asset Management boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 186,168 shares of the biopharmaceutical company's stock after purchasing an additional 15,957 shares during the period. Columbia Asset Management's holdings in Pfizer were worth $4,513,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of PFE. Vanguard Group Inc. raised its holdings in Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. Northern Trust Corp raised its holdings in Pfizer by 6.8% during the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after acquiring an additional 3,943,397 shares during the period. Amundi raised its holdings in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Invesco Ltd. raised its holdings in Pfizer by 2.8% during the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after acquiring an additional 838,198 shares during the period. Finally, Deutsche Bank AG raised its holdings in Pfizer by 7.0% during the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after acquiring an additional 1,846,436 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 6.8%

Shares of NYSE PFE opened at $25.46 on Wednesday. The business's 50 day moving average is $24.55 and its two-hundred day moving average is $24.11. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The stock has a market capitalization of $144.75 billion, a P/E ratio of 13.54, a PEG ratio of 0.77 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the previous year, the firm posted $0.60 earnings per share. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PFE. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a report on Sunday. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.